Evidence map›Paper›PMID 34796110›Full record

ArticleFrontiers in oncology2021

Glia Maturation Factor Beta as a Novel Biomarker and Therapeutic Target for Hepatocellular Carcinoma.

Wan Sun, Changchang Hu, Tianyu Wang, Juan Wang, Jieping Zhang, Furong Gao, Qingjian Ou, Haibin Tian, Caixia Jin, Jingying Xu and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 1 country.

Wan SunDepartment of Ophthalmology of Shanghai Tenth's People Hospital and Laboratory of Clinical Visual Science of Tongji Eye Institute, Tongji University, Shanghai, China.
Changchang HuDepartment of General Surgery of Guizhou Provincial People's Hospital, Guizhou, China.
Tianyu WangTongji University School of Medicine, Shanghai Tenth People's Hospital of Tongji University, Shanghai, China.
Juan WangDepartment of Ophthalmology of Shanghai Tenth's People Hospital and Laboratory of Clinical Visual Science of Tongji Eye Institute, Tongji University, Shanghai, China.
Jieping ZhangDepartment of Ophthalmology of Shanghai Tenth's People Hospital and Laboratory of Clinical Visual Science of Tongji Eye Institute, Tongji University, Shanghai, China.
Furong GaoDepartment of Ophthalmology of Shanghai Tenth's People Hospital and Laboratory of Clinical Visual Science of Tongji Eye Institute, Tongji University, Shanghai, China.
Qingjian OuDepartment of Ophthalmology of Shanghai Tenth's People Hospital and Laboratory of Clinical Visual Science of Tongji Eye Institute, Tongji University, Shanghai, China.
Haibin TianDepartment of Ophthalmology of Shanghai Tenth's People Hospital and Laboratory of Clinical Visual Science of Tongji Eye Institute, Tongji University, Shanghai, China.
Caixia JinDepartment of Ophthalmology of Shanghai Tenth's People Hospital and Laboratory of Clinical Visual Science of Tongji Eye Institute, Tongji University, Shanghai, China.
Jingying XuDepartment of Ophthalmology of Shanghai Tenth's People Hospital and Laboratory of Clinical Visual Science of Tongji Eye Institute, Tongji University, Shanghai, China.
Jingfa ZhangDepartment of Ophthalmology of Shanghai Tenth's People Hospital and Laboratory of Clinical Visual Science of Tongji Eye Institute, Tongji University, Shanghai, China.
Guo-Tong XuDepartment of Ophthalmology of Shanghai Tenth's People Hospital and Laboratory of Clinical Visual Science of Tongji Eye Institute, Tongji University, Shanghai, China.
Lixia LuDepartment of Ophthalmology of Shanghai Tenth's People Hospital and Laboratory of Clinical Visual Science of Tongji Eye Institute, Tongji University, Shanghai, China.
Tongji University · CNShanghai Tenth People's Hospital · CNGuizhou Provincial People's Hospital · CNShanghai First People's Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatocellular carcinoma (HCC) is one of the most common types of cancer. The novel sensitive biomarkers and therapeutic targets are urgently needed for the early diagnosis of HCC and improvement of clinical outcomes. Glia maturation factor-β (GMFB) is a growth and differentiation factor for both glia and neurons and has been found to be tightly involved in inflammation and neurodegeneration conditions. In our study, the expression level of GMFB was significantly up-regulated in patients with HCC and positively co-expression with tumor node metastases (TNM) stage and histopathological grade of HCC. The high expression level of GMFB was remarkably associated with poor overall survival, which mainly occurred in males rather than females. Multivariate analysis revealed GMFB to be an independent prognostic factor for overall survival in patients with HCC. Results of Gene Ontology (GO) and KEGG pathways analysis showed that down-regulation of pathways related to protein translation and mitochondria function were enriched. Protein-protein interaction analysis revealed the central role of mitochondria protein in HCC. The downregulation of genes involved in glycolysis and gluconeogenesis was observed among the co-expression genes of GMFB. Knockdown of GMFB in Hep3B significantly inhibited proliferation, migration, and invasion of Hep3B cells, and also downregulated the expression levels of some of metal matrix proteinase (MMP), increased mtDNA copy number and loss of mitochondrial transmembrane potential. GMFB influences the malignancy rate of HCC possibly through regulation of the expression of MMPs, mtDNA function and glycolysis. We proposed that GMFB was a promising HCC diagnostic and prognostic biomarker and therapeutic target in HCC.

Indexed as

bioinformaticsGMFBhepatocellular carcinomamitochondria functionprognosis

Identifiers

PMID34796110
PMCPMC8593204
OpenAlexW3210745452

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.